T

Thomas F. Gajewski

University of Chicago

ORCID: 0000-0001-5727-3972

Publishes on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research. 656 papers and 56.2k citations.

PubIndex Score98Top 2%How it's scored

🌟#2 Current Senior Leader in Pharmacological Effects of Natural Compounds

656Publications

56.2kTotal Citations

#2in Pharmacological Effects of Natural Compounds

First publication: 1988First senior author: 1972

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses CAR-T cell therapy research Immune Cell Function and Interaction T-cell and B-cell Immunology

Top publicationsby citations

Impact of oncogenic pathways on evasion of antitumour immune responses

Stefani Spranger, Thomas F. Gajewski|Nature reviews. Cancer|2018

Cited by 652

Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

F. Stephen Hodi, David E. Fisher, Christopher L. Corless et al.|Journal of Clinical Oncology|2013

Cited by 594

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

Stefani Spranger, Thomas F. Gajewski|Journal for ImmunoTherapy of Cancer|2014

Cited by 543

Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma

Richard D. Carvajal, Gary K. Schwartz, Paul B. Chapman et al.|JAMA|2014

Cited by 429

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

Tara C. Mitchell, Thomas F. Gajewski|Journal of Clinical Oncology|2018

Cited by 382